The QuicDNA project team are seeking new collaboration opportunities to expand ctDNA testing across Wales.
Aimed at improving lung cancer outcomes, QuicDNA has enhanced lung cancer diagnosis in Wales by integrating ctDNA testing, (liquid biopsies) earlier in the pathway. This has allowed quicker genomic analysis, more precise treatment decisions, and improved patient outcomes.
Launched in 2022, the project has achieved significant advancements for lung cancer diagnostics, with QuicDNA now active across all Health Boards in Wales. This innovation has already demonstrated impact and value for both patients and the health service, with further evaluation to be gathered to support a fully commissioned service in 2025.
A new business proposal is now in development to expand the QuicDNA project nationally to other cancer types under the new programme ‘QuicDNA Max’. Building on the success of the QuicDNA lung cancer project, QuicDNA Max aims to integrate the application of liquid biopsy to other solid tumour types, making liquid biopsies a standard part of the clinical tool kit. As part of its aims, QuicDNA Max will help prepare the system for a larger-scale roll out by fostering education and collaboration, whilst also developing an AI-driven genomic database, to enhance patient outcomes and drive future innovation and research in NHS Wales.
Get involved: Partnering opportunities
To drive this ambitious aim forward, the QuicDNA team are seeking new and existing organisations to partner in a collaborative effort to transform the diagnostic pathway. The project’s existing collaborative approach has seen QuicDNA win multiple healthcare awards, highlighting the power of cross-sector collaboration in driving innovation and systematic change.
Organisations seeking partnership will be required to sign a non-disclosure agreement (NDA). Some existing QuicDNA partners will still be covered under the existing NDA.
For more information please contact Life Sciences Hub Wales via hello@lshubwales.com.
